Altimmune (ALT) announced results from an artificial intelligence-based analysis of biopsies from the IMPACT Phase 2b trial of pemvidutide in patients with metabolic dysfunction-associated steatohepatitis. Highlights from the AI-based analysis of biopsies from patients in the IMPACT Phase 2b trial include: Data for total fibrosis showed 31% of patients in the pemvidutide 1.8 mg group (n = 85), and 12% of patients in the pemvidutide 1.2 mg group achieved a greater than or equal to 60% reduction in the area of fibrosis compared to 8% of placebo-treated patients. Data for early fibrosis showed 34% of patients in the pemvidutide 1.8 mg group, and 24% of patients in the pemvidutide 1.2 mg group achieved greater than or equal to 60% reduction in the area of fibrosis compared to 9% of placebo-treated patients. Data for advanced fibrosis showed 27% of patients in the pemvidutide 1.8 mg group, and 5% of patients in the pemvidutide 1.2 mg group achieved greater than or equal to 60% reduction in the area of fibrosis compared to 11% of placebo-treated patients.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALT:
- Altimmune price target lowered to $14 from $15 at Citizens JMP
- Altimmune Reports Q3 2025 Financial and Business Progress
- Altimmune’s Earnings Call: Financial Growth and Clinical Progress
- Altimmune’s Clinical Progress and Financial Maneuvers Justify Hold Rating Amid Transitional Phase
- Altimmune Enters New Equity Distribution Agreement